EU Priority Medicines Scheme: Early Eligibility, Regular Advice, And A Bonus For SMEs
This article was originally published in SRA
Executive Summary
The European Medicines Agency has confirmed that its proposed priority medicines initiative, PRIME, will be targeted at those new medicines that fulfil the current criteria for accelerated assessment – ie, those that could benefit patients who have no treatment options or that represent a major therapeutic advantage over existing products.